|
Press Releases |
|
 |
|
Monday, April 12, 2021 |
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
Wednesday, March 31, 2021 |
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
Tuesday, March 30, 2021 |
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
Friday, March 26, 2021 |
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
Tuesday, March 23, 2021 |
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
Monday, March 22, 2021 |
|
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan |
Eisai Co., Ltd. announced today that, as part of one strategic investment towards the realization of its medium-term business plan "EWAY2025", it has conducted the groundbreaking ceremony for the construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" ("EMITS") at the Kawashima Industrial Park located in Gifu Prefecture, Japan. more info >> |
|
Eisai Awarded The New Diversity Management Selection 100 |
Eisai Co., Ltd. announced today that it was selected as one of winners of the Ministry of Economy, Trade and Industry (METI) Minister's Award of the New Diversity Management Selection 100 by METI. This marks the first time to be awarded ever since Eisai was included in the New Diversity Management Selection 100 Program. more info >> |
|
Wednesday, March 17, 2021 |
|
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders |
Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer's disease (AD) which modulate immune competence in neurons and glia cells. more info >> |
|
Tuesday, March 16, 2021 |
|
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu |
Eisai Co., Ltd. announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research between Eisai and University College London, has been selected by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
The India Market Entry Dilemma: What's Holding Manufacturers Back
Apr 4, 2025 22:08 HKT/SGT
|
|
|
3rd Future Cross Border Payments Summit, Dubai 2025: Trends Shaping the Future of Payments
Apr 4, 2025 21:15 HKT/SGT
|
|
|
CISO Indonesia 2025: Elevating Cybersecurity Strategies for a Resilient Digital Future
Apr 4, 2025 20:50 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 4, 2025 20:40 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 4, 2025 19:41 HKT/SGT
|
|
|
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 4, 2025 15:56 JST
|
|
|
Asiaray Achieves Net Profit Turnaround of RMB10.4 Million in 2024
Apr 4, 2025 14:39 HKT/SGT
|
|
|
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 4, 2025 9:04 JST
|
|
|
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 3, 2025 22:10 JST
|
|
|
Connect Marketplace Hong Kong 2025 Concludes Successfully
Apr 3, 2025 18:29 HKT/SGT
|
|
|
JBM Healthcare Completes Acquisition of 90% Interest in Tin Hee Tong
Apr 3, 2025 17:30 HKT/SGT
|
|
|
Guinean Artist Elie Kamano to Release New Single Exploring Africa's Colonial Past
Apr 3, 2025 17:00 HKT/SGT
|
|
|
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025
Apr 3, 2025 17:00 HKT/SGT
|
|
|
JF SmartInvest Holdings Ltd Announces 2024 Annual Results
Apr 3, 2025 15:59 HKT/SGT
|
|
|
AEON CREDIT SERVICE (ASIA) COMPANY LIMITED FY2024/25 Revenue Up to HK$1,759.3 million with Net Profit of HK$400.5 million
Apr 3, 2025 14:04 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|